Aaron Michels
Concepts (332)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 72 | 2026 | 3837 | 7.540 |
Why?
| | Receptors, Antigen, T-Cell | 16 | 2025 | 727 | 3.360 |
Why?
| | Autoantigens | 17 | 2025 | 427 | 3.260 |
Why?
| | Insulin | 31 | 2026 | 2501 | 3.020 |
Why?
| | Islets of Langerhans | 18 | 2026 | 829 | 2.670 |
Why?
| | Autoantibodies | 23 | 2026 | 1492 | 2.570 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 195 | 1.840 |
Why?
| | T-Lymphocytes | 13 | 2025 | 2036 | 1.830 |
Why?
| | Insulin-Secreting Cells | 10 | 2025 | 389 | 1.620 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 263 | 1.600 |
Why?
| | HLA Antigens | 4 | 2025 | 232 | 1.500 |
Why?
| | Autoimmunity | 15 | 2025 | 927 | 1.480 |
Why?
| | CD4-Positive T-Lymphocytes | 15 | 2025 | 1130 | 1.440 |
Why?
| | Hypoglycemic Agents | 10 | 2026 | 1403 | 1.400 |
Why?
| | Immunotherapy | 8 | 2025 | 659 | 1.350 |
Why?
| | Insulin Antibodies | 5 | 2026 | 103 | 1.330 |
Why?
| | Antibodies, Monoclonal | 5 | 2020 | 1477 | 1.210 |
Why?
| | Peptides | 7 | 2026 | 981 | 1.210 |
Why?
| | Autoimmune Diseases | 5 | 2019 | 469 | 1.070 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2018 | 367 | 1.000 |
Why?
| | HLA-DQ Antigens | 7 | 2019 | 173 | 0.980 |
Why?
| | Immunologic Factors | 3 | 2019 | 251 | 0.930 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 223 | 0.900 |
Why?
| | Antigen Presentation | 2 | 2018 | 214 | 0.830 |
Why?
| | Protein Precursors | 3 | 2021 | 135 | 0.800 |
Why?
| | Melanoma | 2 | 2022 | 808 | 0.800 |
Why?
| | Peptide Fragments | 7 | 2026 | 702 | 0.780 |
Why?
| | Humans | 82 | 2026 | 143879 | 0.760 |
Why?
| | B7-H1 Antigen | 3 | 2021 | 234 | 0.750 |
Why?
| | Models, Immunological | 2 | 2015 | 101 | 0.740 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 103 | 0.730 |
Why?
| | Methyldopa | 2 | 2019 | 6 | 0.710 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2025 | 54 | 0.650 |
Why?
| | HLA-DQ beta-Chains | 1 | 2020 | 59 | 0.640 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.620 |
Why?
| | Disease Susceptibility | 1 | 2021 | 354 | 0.620 |
Why?
| | Health Fairs | 1 | 2019 | 10 | 0.610 |
Why?
| | Interferon-gamma | 2 | 2021 | 791 | 0.610 |
Why?
| | Stevens-Johnson Syndrome | 2 | 2019 | 38 | 0.600 |
Why?
| | Antigens | 4 | 2018 | 350 | 0.590 |
Why?
| | Child | 31 | 2026 | 22784 | 0.560 |
Why?
| | Preventive Medicine | 1 | 2018 | 40 | 0.550 |
Why?
| | Proinsulin | 2 | 2017 | 52 | 0.530 |
Why?
| | Mice, Inbred NOD | 10 | 2026 | 611 | 0.530 |
Why?
| | Alleles | 5 | 2022 | 893 | 0.520 |
Why?
| | Epitopes | 5 | 2025 | 489 | 0.520 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 210 | 0.520 |
Why?
| | Adolescent | 28 | 2026 | 22529 | 0.500 |
Why?
| | Antibody Formation | 1 | 2018 | 297 | 0.500 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.480 |
Why?
| | Influenza, Human | 1 | 2022 | 636 | 0.480 |
Why?
| | Genetic Predisposition to Disease | 8 | 2025 | 2423 | 0.460 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 125 | 0.460 |
Why?
| | Major Histocompatibility Complex | 2 | 2013 | 233 | 0.450 |
Why?
| | Graft Rejection | 1 | 2018 | 551 | 0.440 |
Why?
| | Rituximab | 1 | 2016 | 206 | 0.440 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2026 | 929 | 0.440 |
Why?
| | HLA-D Antigens | 1 | 2014 | 30 | 0.430 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1143 | 0.430 |
Why?
| | Diet Therapy | 1 | 2014 | 37 | 0.430 |
Why?
| | Hypoglycemia | 3 | 2016 | 473 | 0.420 |
Why?
| | Addison Disease | 1 | 2014 | 39 | 0.410 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 95 | 0.410 |
Why?
| | Biomarkers | 4 | 2025 | 4244 | 0.410 |
Why?
| | Adrenal Glands | 1 | 2014 | 79 | 0.410 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 965 | 0.410 |
Why?
| | Antibodies | 1 | 2015 | 402 | 0.400 |
Why?
| | Hormone Replacement Therapy | 1 | 2014 | 102 | 0.390 |
Why?
| | Blood Glucose | 5 | 2026 | 2319 | 0.390 |
Why?
| | Young Adult | 18 | 2025 | 13998 | 0.390 |
Why?
| | Child, Preschool | 16 | 2026 | 11782 | 0.380 |
Why?
| | Female | 41 | 2026 | 77456 | 0.370 |
Why?
| | Disease Progression | 6 | 2021 | 2862 | 0.370 |
Why?
| | Mass Screening | 3 | 2019 | 1337 | 0.370 |
Why?
| | Prediabetic State | 1 | 2015 | 255 | 0.360 |
Why?
| | Male | 37 | 2026 | 71702 | 0.360 |
Why?
| | Infant | 11 | 2026 | 10022 | 0.340 |
Why?
| | C-Peptide | 6 | 2026 | 179 | 0.340 |
Why?
| | Animals | 24 | 2026 | 38080 | 0.340 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 82 | 0.330 |
Why?
| | Glycine | 1 | 2011 | 187 | 0.320 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.320 |
Why?
| | Struma Ovarii | 1 | 2010 | 7 | 0.320 |
Why?
| | Macromolecular Substances | 1 | 2010 | 224 | 0.310 |
Why?
| | Endocrine System Diseases | 1 | 2010 | 35 | 0.310 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 859 | 0.300 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 335 | 0.300 |
Why?
| | Adult | 29 | 2026 | 40116 | 0.290 |
Why?
| | Transcription Factor 7-Like 2 Protein | 2 | 2018 | 26 | 0.280 |
Why?
| | Haplotypes | 3 | 2020 | 496 | 0.270 |
Why?
| | Carbamazepine | 2 | 2019 | 21 | 0.270 |
Why?
| | Inflammation | 2 | 2017 | 2882 | 0.260 |
Why?
| | Glutamate Decarboxylase | 4 | 2017 | 166 | 0.260 |
Why?
| | Pediatrics | 1 | 2015 | 1127 | 0.250 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2020 | 2580 | 0.250 |
Why?
| | Neoplasms | 2 | 2020 | 2813 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2021 | 928 | 0.240 |
Why?
| | Mice | 14 | 2026 | 18423 | 0.240 |
Why?
| | Antilymphocyte Serum | 2 | 2016 | 59 | 0.240 |
Why?
| | Middle Aged | 20 | 2022 | 35429 | 0.230 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2016 | 89 | 0.230 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2026 | 856 | 0.230 |
Why?
| | History, 21st Century | 2 | 2018 | 220 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2026 | 399 | 0.220 |
Why?
| | History, 20th Century | 2 | 2018 | 328 | 0.220 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2024 | 719 | 0.210 |
Why?
| | Endocrinology | 1 | 2025 | 77 | 0.210 |
Why?
| | Pluripotent Stem Cells | 2 | 2022 | 81 | 0.210 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2024 | 135 | 0.210 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 587 | 0.200 |
Why?
| | Hybridomas | 3 | 2020 | 234 | 0.200 |
Why?
| | Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.200 |
Why?
| | Age of Onset | 1 | 2025 | 549 | 0.200 |
Why?
| | Lipodystrophy | 1 | 2023 | 14 | 0.190 |
Why?
| | Protein Binding | 3 | 2021 | 2270 | 0.190 |
Why?
| | Contrast Media | 1 | 2026 | 483 | 0.190 |
Why?
| | CD3 Complex | 2 | 2020 | 110 | 0.190 |
Why?
| | Drug Delivery Systems | 1 | 2026 | 377 | 0.190 |
Why?
| | Histocompatibility Antigens | 1 | 2021 | 108 | 0.170 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2944 | 0.170 |
Why?
| | Insulin, Regular, Human | 1 | 2020 | 48 | 0.170 |
Why?
| | Rhizotomy | 1 | 2000 | 5 | 0.160 |
Why?
| | Polyethylene Glycols | 2 | 2016 | 642 | 0.160 |
Why?
| | Virus Diseases | 2 | 2015 | 218 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2181 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1044 | 0.160 |
Why?
| | Brachial Plexus | 1 | 2000 | 34 | 0.160 |
Why?
| | Retroviridae | 1 | 2020 | 104 | 0.160 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2021 | 208 | 0.150 |
Why?
| | Muscle Spasticity | 1 | 2000 | 61 | 0.150 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 9 | 0.150 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.150 |
Why?
| | Arm | 1 | 2000 | 109 | 0.150 |
Why?
| | Case-Control Studies | 3 | 2022 | 3634 | 0.150 |
Why?
| | Immunoassay | 1 | 2020 | 110 | 0.150 |
Why?
| | Stem Cells | 2 | 2021 | 619 | 0.150 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 67 | 0.150 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 38 | 0.150 |
Why?
| | Treatment Outcome | 6 | 2026 | 11391 | 0.150 |
Why?
| | Genotype | 2 | 2015 | 1877 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 552 | 0.150 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2019 | 174 | 0.140 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 111 | 0.140 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 146 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 4164 | 0.140 |
Why?
| | Models, Molecular | 2 | 2015 | 1624 | 0.140 |
Why?
| | Transglutaminases | 2 | 2016 | 158 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 163 | 0.130 |
Why?
| | Community Health Services | 1 | 2019 | 234 | 0.130 |
Why?
| | Genetic Heterogeneity | 1 | 2017 | 64 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 357 | 0.130 |
Why?
| | Tissue Donors | 2 | 2021 | 412 | 0.130 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 28 | 0.130 |
Why?
| | Radioimmunoassay | 1 | 2016 | 168 | 0.130 |
Why?
| | Amino Acid Sequence | 3 | 2017 | 2167 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2021 | 668 | 0.120 |
Why?
| | Immune Tolerance | 2 | 2026 | 384 | 0.120 |
Why?
| | Luminescence | 1 | 2016 | 38 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 1010 | 0.120 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2194 | 0.120 |
Why?
| | Mutation | 3 | 2015 | 4061 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 842 | 0.120 |
Why?
| | Dideoxynucleosides | 1 | 2015 | 21 | 0.120 |
Why?
| | Luminescent Measurements | 1 | 2016 | 76 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 78 | 0.120 |
Why?
| | Sensitivity and Specificity | 4 | 2026 | 1986 | 0.110 |
Why?
| | Antigen-Presenting Cells | 1 | 2015 | 163 | 0.110 |
Why?
| | Immunologic Memory | 1 | 2017 | 365 | 0.110 |
Why?
| | Monocytes | 2 | 2016 | 545 | 0.110 |
Why?
| | Abatacept | 1 | 2014 | 57 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 398 | 0.110 |
Why?
| | Vitamin B Complex | 1 | 2014 | 40 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 169 | 0.100 |
Why?
| | Early Medical Intervention | 1 | 2014 | 60 | 0.100 |
Why?
| | Niacinamide | 1 | 2014 | 82 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 101 | 0.100 |
Why?
| | Multifactorial Inheritance | 1 | 2015 | 210 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2019 | 884 | 0.100 |
Why?
| | Chromogranin A | 1 | 2013 | 42 | 0.100 |
Why?
| | CD4 Antigens | 1 | 2013 | 146 | 0.100 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 48 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 241 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 311 | 0.100 |
Why?
| | Immunoconjugates | 1 | 2014 | 128 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2014 | 148 | 0.090 |
Why?
| | Primary Prevention | 1 | 2014 | 202 | 0.090 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 105 | 0.090 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 171 | 0.090 |
Why?
| | Colorado | 2 | 2021 | 4669 | 0.090 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 226 | 0.090 |
Why?
| | Celiac Disease | 1 | 2016 | 305 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 626 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1090 | 0.090 |
Why?
| | Incidence | 1 | 2019 | 2854 | 0.090 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 190 | 0.090 |
Why?
| | Pancreas, Artificial | 1 | 2013 | 99 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2018 | 698 | 0.090 |
Why?
| | Alum Compounds | 1 | 2011 | 27 | 0.090 |
Why?
| | Aged | 5 | 2021 | 25377 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 869 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 352 | 0.080 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 107 | 0.080 |
Why?
| | Cytokines | 2 | 2017 | 2099 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 577 | 0.080 |
Why?
| | Dietary Proteins | 1 | 2011 | 135 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2014 | 503 | 0.080 |
Why?
| | Thyroglobulin | 1 | 2010 | 30 | 0.080 |
Why?
| | Whole Body Imaging | 1 | 2010 | 26 | 0.080 |
Why?
| | Radionuclide Imaging | 1 | 2010 | 117 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1507 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 98 | 0.080 |
Why?
| | Iodine Radioisotopes | 1 | 2010 | 140 | 0.080 |
Why?
| | Self Tolerance | 1 | 2009 | 26 | 0.070 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 76 | 0.070 |
Why?
| | Prospective Studies | 4 | 2026 | 7918 | 0.070 |
Why?
| | Organ Specificity | 1 | 2010 | 311 | 0.070 |
Why?
| | Hysterectomy | 1 | 2010 | 139 | 0.070 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 29 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 197 | 0.070 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1272 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 451 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 380 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1675 | 0.070 |
Why?
| | Vaccines | 1 | 2011 | 410 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2621 | 0.060 |
Why?
| | Microbubbles | 1 | 2026 | 53 | 0.060 |
Why?
| | Histocompatibility Testing | 2 | 2017 | 122 | 0.060 |
Why?
| | Area Under Curve | 2 | 2016 | 328 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 589 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 6055 | 0.060 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 177 | 0.050 |
Why?
| | Risk Assessment | 1 | 2014 | 3585 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2026 | 376 | 0.050 |
Why?
| | Perilipin-1 | 1 | 2023 | 17 | 0.050 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 13 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2022 | 2023 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1831 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2026 | 4544 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 477 | 0.050 |
Why?
| | Ultrasonography | 1 | 2026 | 773 | 0.050 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 47 | 0.040 |
Why?
| | Psychology, Child | 1 | 1981 | 39 | 0.040 |
Why?
| | Transcription Factors | 1 | 2009 | 1754 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 171 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2000 | 127 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 125 | 0.040 |
Why?
| | HLA-B15 Antigen | 1 | 2019 | 11 | 0.040 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 94 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 138 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2020 | 273 | 0.040 |
Why?
| | Hand | 1 | 2000 | 166 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2020 | 184 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2019 | 219 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1192 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 337 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2020 | 342 | 0.040 |
Why?
| | Psychotic Disorders | 1 | 1981 | 179 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2018 | 185 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2023 | 654 | 0.030 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2018 | 83 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 404 | 0.030 |
Why?
| | Gene Editing | 1 | 2018 | 89 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 492 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5898 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 258 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2018 | 187 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 398 | 0.030 |
Why?
| | Receptors, CXCR3 | 1 | 2016 | 16 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 37 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 747 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 73 | 0.030 |
Why?
| | Zinc Transporter 8 | 1 | 2016 | 63 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 522 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 203 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2016 | 116 | 0.030 |
Why?
| | Skin | 1 | 2019 | 774 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 422 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 294 | 0.030 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 53 | 0.030 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 6 | 0.030 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.030 |
Why?
| | Chromatography, Gel | 1 | 2014 | 129 | 0.030 |
Why?
| | Allylamine | 1 | 2013 | 6 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 197 | 0.030 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 11 | 0.030 |
Why?
| | Bromocriptine | 1 | 2013 | 31 | 0.030 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 25 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2832 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2014 | 89 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4183 | 0.030 |
Why?
| | Overweight | 1 | 2018 | 598 | 0.030 |
Why?
| | Risk | 1 | 2016 | 906 | 0.020 |
Why?
| | Drug Combinations | 1 | 2014 | 376 | 0.020 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 51 | 0.020 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 48 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1372 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 171 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 10673 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2016 | 475 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 434 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 189 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1294 | 0.020 |
Why?
| | Thiazolidinediones | 1 | 2013 | 136 | 0.020 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 138 | 0.020 |
Why?
| | Leptin | 1 | 2013 | 239 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2014 | 392 | 0.020 |
Why?
| | Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2013 | 252 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 644 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3381 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2939 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 333 | 0.020 |
Why?
| | Thymus Gland | 1 | 2011 | 318 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1092 | 0.020 |
Why?
| | Metformin | 1 | 2013 | 331 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3210 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1505 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 3013 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2000 | 2912 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5220 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 7042 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 3046 | 0.010 |
Why?
| | Registries | 1 | 2013 | 2245 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5762 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2118 | 0.010 |
Why?
| | Language Development Disorders | 1 | 1981 | 40 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8077 | 0.010 |
Why?
| | Mother-Child Relations | 1 | 1981 | 136 | 0.010 |
Why?
| | Child Behavior Disorders | 1 | 1981 | 143 | 0.010 |
Why?
| | Family | 1 | 1981 | 683 | 0.010 |
Why?
| | United States | 1 | 2013 | 15592 | 0.010 |
Why?
| | Communication | 1 | 1981 | 956 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|